Search research articles
Contact Us
Filters
Showing results (61-70 of 118) with videos related to
Page
of 12
Sort By:
Pediatric Neurology
|
September 26, 2020
Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests
Natalie F Miller, Lindsay N Alfano, Megan A Iammarino, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
April 25, 2015
Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies
Christopher F Spurney, Francis M McCaffrey, Avital Cnaan, et al.
Human Molecular Genetics
|
January 5, 2010
Myosin binding protein C1: a novel gene for autosomal dominant distal arthrogryposis type 1
Christina A Gurnett, David M Desruisseau, Kevin McCall, et al.
Journal of Neuromuscular Diseases
|
February 3, 2020
Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2
Jacqueline Glascock, Jacinda Sampson, Anne M Connolly, et al.
World Journal of Pediatrics : WJP
|
March 25, 2019
Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy
Qing Ke, Zheng-Yan Zhao, Jerry R Mendell, et al.
Journal of Neuromuscular Diseases
|
June 14, 2021
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
Craig M McDonald, Perry B Shieh, Hoda Z Abdel-Hamid, et al.
Plos Currents
|
January 25, 2014
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy
Hugh D Allen, Kevin M Flanigan, Philip T Thrush, et al.
JAMA Neurology
|
May 27, 2020
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
Paula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Pediatric Neurology
|
July 16, 2021
Validity and Reliability of the Neuromuscular Gross Motor Outcome
Lindsay N Alfano, Megan A Iammarino, Natalie F Reash, et al.
Muscle & Nerve
|
April 25, 2020
Spinal muscular atrophy care in the COVID-19 pandemic era
Aravindhan Veerapandiyan, Anne M Connolly, Richard S Finkel, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 118) with videos related to
Sort By:
Page
of 12
Pediatric Neurology
|
September 26, 2020
Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests
Natalie F Miller, Lindsay N Alfano, Megan A Iammarino, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
April 25, 2015
Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies
Christopher F Spurney, Francis M McCaffrey, Avital Cnaan, et al.
Human Molecular Genetics
|
January 5, 2010
Myosin binding protein C1: a novel gene for autosomal dominant distal arthrogryposis type 1
Christina A Gurnett, David M Desruisseau, Kevin McCall, et al.
Journal of Neuromuscular Diseases
|
February 3, 2020
Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2
Jacqueline Glascock, Jacinda Sampson, Anne M Connolly, et al.
World Journal of Pediatrics : WJP
|
March 25, 2019
Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy
Qing Ke, Zheng-Yan Zhao, Jerry R Mendell, et al.
Journal of Neuromuscular Diseases
|
June 14, 2021
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
Craig M McDonald, Perry B Shieh, Hoda Z Abdel-Hamid, et al.
Plos Currents
|
January 25, 2014
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy
Hugh D Allen, Kevin M Flanigan, Philip T Thrush, et al.
JAMA Neurology
|
May 27, 2020
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
Paula R Clemens, Vamshi K Rao, Anne M Connolly, et al.
Pediatric Neurology
|
July 16, 2021
Validity and Reliability of the Neuromuscular Gross Motor Outcome
Lindsay N Alfano, Megan A Iammarino, Natalie F Reash, et al.
Muscle & Nerve
|
April 25, 2020
Spinal muscular atrophy care in the COVID-19 pandemic era
Aravindhan Veerapandiyan, Anne M Connolly, Richard S Finkel, et al.
Page
of 12